Transcenta Therapeutics Email Format

Biotechnology ResearchFlorida, United States51-200 Employees

Transcenta Therapeutics is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics, integrating discovery, development, and manufacturing capabilities. It has a global footprint spanning China and the United States, with a headquarters and discovery, clinical, and translational research center in Suzhou, a manufacturing facility in Hangzhou, clinical development centers in Beijing, Shanghai, and Guangzhou, and a presence in Princeton, United States. The company is advancing nine therapeutic antibody molecules for oncology and selected non-oncology indications, including bone and kidney disorders. It listed on the Main Board of the Hong Kong Stock Exchange in September 2021. In 2026, Transcenta appointed Christopher Hwang as Head of Global Partnerships for its Highly Intensified Continuous Bioprocessing platform.

Sign up for free to view info

Company overview Employee directory